Barclays analyst Peter Warendorf initiated coverage of LifeStance (LFST) with an Overweight rating and $8 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance management to meet virtually with KeyBanc
- LifeStance management to meet virtually with BTIG
- LifeStance initiated with an Outperform at BMO Capital
- Positive Outlook for LifeStance Health Group: Overcoming Challenges and Driving Growth with Strategic Initiatives
- Strong Performance and Promising Outlook: Richard Close Reaffirms Buy Rating for Lifestance Health Group